Your browser doesn't support javascript.
loading
LONG-TERM USE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Begaj, Tedi; Jeong, Daeun; Park, Jong G; Runner, Margaret M; Capone, Antonio; Dass, A Bawa; Drenser, Kimberly A; Faia, Lisa J; Farley, Nathan D; Garretson, Bruce R; Hassan, Tarek S; Mahmoud, Tamer H; Margherio, Alan; Raphaelian, Paul V; Randhawa, Sandeep; Ruby, Alan J; Sneed, Scott; Rao, Prethy; Wolfe, Jeremy D; Williams, George A.
  • Begaj T; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Jeong D; Oakland University William Beaumont, Rochester, Michigan.
  • Park JG; Oakland University William Beaumont, Rochester, Michigan.
  • Runner MM; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Capone A; Oakland University William Beaumont, Rochester, Michigan.
  • Dass AB; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Drenser KA; Oakland University William Beaumont, Rochester, Michigan.
  • Faia LJ; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Farley ND; Oakland University William Beaumont, Rochester, Michigan.
  • Garretson BR; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Hassan TS; Oakland University William Beaumont, Rochester, Michigan.
  • Mahmoud TH; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Margherio A; Oakland University William Beaumont, Rochester, Michigan.
  • Raphaelian PV; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Randhawa S; Oakland University William Beaumont, Rochester, Michigan.
  • Ruby AJ; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Sneed S; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Rao P; Oakland University William Beaumont, Rochester, Michigan.
  • Wolfe JD; Associated Retinal Consultants/Beaumont Health, Royal Oak, Michigan.
  • Williams GA; Oakland University William Beaumont, Rochester, Michigan.
Retina ; 44(2): 222-229, 2024 Feb 01.
Article en En | MEDLINE | ID: mdl-37903288
ABSTRACT

PURPOSE:

Although pivotal trials have demonstrated efficacy of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration, there is a paucity of clinical data about the long-term (>5 years) treatment.

METHODS:

Retrospective analysis of all patients with neovascular age-related macular degeneration who were actively treated, had received >40 anti-vascular endothelial growth factor injections, and were followed for ≥5 years. Snellen-corrected visual acuity, initial drug choice, and times elapsed between treatments were collected. Rates of endophthalmitis and outcomes of submacular hemorrhage were also evaluated.

RESULTS:

A total of 88 patients (162 eyes) met the inclusion criteria the average patient age was 86.3 years with an average follow-up period of 7.6 years. The average total number of injections per eye was 69 (18.0 SD); a total of 11,208 injections were given throughout the study period, and 6 cases (0.05%) of endophthalmitis were observed. Overall, there was a clinical and statistical difference in average Snellen-corrected visual acuity at Injections #2,#3, #4, #5, #6, #10, and #20, as compared with baseline ( P = 0.03, P < 0.01, P = 0.02, P < 0.01, P = 0.01, P = 0.01, P < 0.01, respectively). Patients in the Snellen-corrected visual acuity subgroup 20/20 to 20/40 maintained vision until injection #30. Seven eyes experienced a visually significant submacular hemorrhage.

CONCLUSION:

This neovascular age-related macular degeneration cohort received on average eight anti-vascular endothelial growth factor injections per year for approximately 8 years; eyes with good (≥20/40) initial baseline vision maintained their visual acuity, whereas those with worse Snellen-corrected visual acuity (≤20/50) had a robust initial improvement that diminished with time. Most patients were maintained on the same initial drug of choice and the rate of endophthalmitis was low.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Endoftalmitis / Degeneración Macular Húmeda / Degeneración Macular Límite: Aged80 / Child / Child, preschool / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Endoftalmitis / Degeneración Macular Húmeda / Degeneración Macular Límite: Aged80 / Child / Child, preschool / Humans Idioma: En Año: 2024 Tipo del documento: Article